Arbutus Biopharma Corp (ABUS) - 2024 Annual Report Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2024. Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious diseases, primarily developing a functional cure for chronic hepatitis B (cHBV) via its lead candidates imdusiran (AB-729) and AB-101. The company also holds significant intellectual property rights regarding Lipid Nanoparticle (LNP) delivery technology, which is the subject of ongoing patent infringement litigation against Moderna and Pfizer/BioNTech.
During 2024, the company streamlined operations by ceasing discovery efforts, discontinuing the IM-PROVE III clinical trial, and reducing its workforce by 40%. In Q1 2025, the Board was entirely replaced, and a new management team was appointed, initiating a further 57% workforce reduction and the closure of the Warminster, PA headquarters.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $6.2 million | $18.1 million |
| Net Loss | $(69.9) million | $(72.8) million |
| Loss Per Share (Basic/Diluted) | $(0.38) | $(0.44) |
| Operating Expenses | $82.5 million | $96.2 million |
| Cash, Cash Equivalents & Investments | $122.6 million | $126.0 million |
| Net Cash Used in Operating Activities | $(64.9) million | $(85.9) million |
| Outstanding Debt | $0 | $0 |
Note: Revenue includes $2.3 million in non-cash royalty revenue related to the sale of future royalties to OMERS.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by $12.0 million (66%) year-over-year. This was driven by a $9.3 million decrease in revenue recognized from the Qilu Pharmaceutical license agreement (due to reduced effort required for manufacturing technology transfer) and a $2.7 million decrease in royalties from Alnylam's ONPATTRO due to sales cannibalization by Alnylam's newer product, AMVUTTRA.
- Expense Reduction: Operating expenses decreased by $13.7 million. Research and Development (R&D) expenses dropped $19.7 million due to the discontinuation of the IM-PROVE III trial, cessation of discovery efforts, and workforce reductions. General and Administrative (G&A) expenses remained relatively flat, decreasing only $0.4 million.
- Restructuring Costs: The company incurred $3.7 million in one-time restructuring charges in Q3 2024 related to the initial workforce reduction and trial discontinuation.
- Contingent Consideration: The fair value of contingent consideration liability increased by $2.6 million to $10.2 million, driven by an increased assessment of the probability of success for imdusiran following positive clinical data from the IM-PROVE I trial.
Guidance, Outlook, and Risks
Management Commentary & Outlook: The new Board and management team are currently reviewing the pipeline and development plans for hepatitis B programs. The company expects to significantly reduce net cash burn in 2025 compared to 2024 due to organizational changes. However, substantial additional capital will be required to continue active development. The company anticipates incurring a one-time restructuring charge of approximately $11 million to $13 million in Q1 2025 related to the recent workforce reduction and headquarters exit.
Key Risks and Contingencies:
- Litigation: The company is engaged in high-stakes patent infringement lawsuits against Moderna (trial set for September 24, 2025) and Pfizer/BioNTech (trial date expected in 2025). Five international lawsuits against Moderna were filed in March 2025. Outcomes are uncertain and could materially impact financial results.
- Regulatory Holds: The FDA placed a clinical hold on the AB-101 IND application in April 2023. While a Phase 1 trial proceeded in New Zealand, the FDA has not yet lifted the hold for U.S. trials, creating uncertainty for the AB-101 program.
- Liquidity: While the company has $122.6 million in cash and investments as of year-end, it has no product revenues and expects to continue incurring losses. Future funding may require dilutive equity issuances or strategic partnerships.
- Partnership Dependencies: Revenue relies heavily on licensing partners (Alnylam, Qilu). Declining sales of ONPATTRO and the strategic shift of partner Barinthus (postponing VTP-300 development) pose risks to future revenue streams and collaboration plans.
Investor Verification Checklist
- Cash Runway: Verify the updated cash burn rate post-Q1 2025 restructuring and the sufficiency of current liquidity ($122.6M) to fund operations through the pipeline review completion.
- Litigation Status: Monitor the claim construction rulings and trial schedules for the Moderna and Pfizer/BioNTech lawsuits, as these represent potential significant upside or downside.
- AB-101 Clinical Hold: Confirm the status of the FDA clinical hold on AB-101 and the timeline for potential U.S. trial initiation.
- Pipeline Review Outcome: Await the results of the new management's review of the hepatitis B development plans, which may lead to further program discontinuations or strategic pivots.
- Restructuring Costs: Track the actual Q1 2025 restructuring charges (estimated $11M-$13M) and their impact on the 2025 cash position.